Veracyte, Inc. - Common Stock (NQ:VCYT)

49.00 UNCHANGED

Delayed Quote Updated: 4:00 PM EST, Nov 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Veracyte, Inc. - Common Stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Veracyte Announces New Data Suggesting Afirma Testing Can Help Personalize Care for Patients with Thyroid Nodules

February 01, 2023

From Veracyte, Inc.

Via Business Wire

Better Long-Term Buy in 2023: Exact Sciences or Veracyte? ↗

January 24, 2023

As cancer screenings are becoming covered more often, both companies stand to gain.

Via The Motley Fool

Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors

January 23, 2023

From Exagen Inc.

Via GlobeNewswire

Expert Ratings for Veracyte ↗

January 05, 2023

Via Benzinga

Veracyte Earnings Perspective: Return On Capital Employed ↗

November 16, 2022

Via Benzinga

Raymond James Upgrades Natera & Myriad Genetics, While Downgrading This Stock ↗

January 18, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2023 ↗

January 18, 2023

Via Benzinga

This Small-Cap Stock Is a No-Brainer Buy ↗

January 18, 2023

This genomic test maker's stock was beaten down in 2022. But it could be heading for a rebound this year.

Via The Motley Fool

Data Published in JCEM Demonstrate Strong Real-World Performance of Veracyte’s Afirma GSC in Thyroid Cancer Diagnosis

December 15, 2022

From Veracyte, Inc.

Via Business Wire

Veracyte Stock Showing Market Leadership; Earns 93 RS Rating ↗

December 01, 2022

Veracyte shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.

Via Investor's Business Daily

US Stocks Open Lower; Nasdaq Drops 100 Points ↗

November 03, 2022

U.S. stocks traded lower this morning, with the Nasdaq Composite dropping around 100 points on Thursday. The Federal Reserve, on Wednesday, raised interest rates by 75 bps.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023 ↗

January 05, 2023

Via Benzinga

Why Apyx Medical Shares Dipped Over 60%; Here Are 123 Biggest Movers From Yesterday ↗

November 11, 2022

Gainers

Via Benzinga

Why Greenhill Shares Climbed Around 25%; Here Are 100 Biggest Movers From Yesterday ↗

November 04, 2022

Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) shares jumped 242.8% to close at $105.72 on Thursday. The company announced a strategic plan to enter into the clean energy industry.

Via Benzinga

Why Lincoln National Shares Are Trading Lower By 31%? Here Are 72 Stocks Moving In Thursday's Session ↗

November 03, 2022

Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) gained 64% to $50.60.

Via Benzinga

Veracyte Announces Third Quarter 2022 Financial Results

November 02, 2022

From Veracyte, Inc.

Via Business Wire

Earnings Scheduled For November 2, 2022 ↗

November 02, 2022

Companies Reporting Before The Bell • Nomura Holdings (NYSE:NMR) is likely to report earnings for its second quarter.

Via Benzinga

Veracyte Announces Three Abstracts to Be Presented at SITC 2022 Annual Meeting

November 01, 2022

From Veracyte, Inc.

Via Business Wire

Veracyte to Participate in the Credit Suisse 31st Annual Healthcare Conference

October 27, 2022

From Veracyte, Inc.

Via Business Wire

New Data Suggest Decipher GRID-Derived Genomic Signature Can Help Identify Men with Prostate Cancer Who Should Receive High-Dose Radiotherapy

October 25, 2022

From Veracyte, Inc.

Via Business Wire

Veracyte Data Presented at ATA Annual Meeting Provide New Insights into Molecular Underpinnings of Thyroid Cancer

October 24, 2022

From Veracyte, Inc.

Via Business Wire

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

October 19, 2022

Gainers ASLAN Pharma (NASDAQ:ASLN) stock moved upwards by 13.7% to $0.54 during Wednesday's after-market session. The market value of their outstanding shares is at $37.6 million.

Via Benzinga

New Data Presented at CHEST 2022 Reinforce Clinical Value of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer

October 18, 2022

From Veracyte, Inc.

Via Business Wire

Veracyte to Release Third Quarter 2022 Financial Results on November 2, 2022

October 13, 2022

From Veracyte, Inc.

Via Business Wire

New Data Published in JNCI Demonstrate Veracyte’s Decipher Prostate Genomic Classifier May Improve Identification of Aggressive Prostate Cancer in African American Men

September 22, 2022

From Veracyte, Inc.

Via Business Wire

Veracyte Names John Leite, Ph.D., as General Manager of Pulmonology & Market Access

September 13, 2022

From Veracyte, Inc.

Via Business Wire

New Data Presented at ESMO 2022 Show Veracyte’s Decipher Prostate Genomic Classifier May Help Inform Personalized Treatment Decisions in Men with Advanced Prostate Cancer

September 11, 2022

From Veracyte, Inc.

Via Business Wire

New Data Suggest Veracyte’s Envisia Genomic Classifier Can Help Predict Disease Progression in Interstitial Lung Disease Patients Treated with Combination Immunosuppressive Therapy

September 07, 2022

From Veracyte, Inc.

Via Business Wire

Veracyte to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

September 01, 2022

From Veracyte, Inc.

Via Business Wire

Veracyte Announces Seven Abstracts to Be Presented at ESMO Congress 2022

August 31, 2022

From Veracyte, Inc.

Via Business Wire

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.